厄贝沙坦/氢氯噻嗪与硝苯地平控释片联合治疗高血压疗效评价

    Irbesartan/hydrochlorothiazide tablets and nifedipine controlled-release tablets in moderate to severe enssential hypertension

    • 摘要: 目的: 观察厄贝沙坦/氢氯噻嗪片(含厄贝沙坦150 mg,氢氯噻嗪12.5 mg)与硝苯地平控释片(含硝苯地平30 mg)联合治疗高血压的临床疗效。方法: 选择高血压患者78例,随机分为A组(口服厄贝沙坦/氢氯噻嗪片150 mg,每日1次)、B组(口服硝苯地平控释片30 mg,每日1次)、C组(晨服厄贝沙坦/氢氯噻嗪片150 mg,睡前服用硝苯地平控释片30 mg,每日1次),疗程均为12周。结果: 3组患者血压均有下降(P < 0.01),总有效率A组为61.9%,B组为64.0%,C组为93.8%,差异有统计学意义(P < 0.05)。结论: 厄贝沙坦/氢氯噻嗪联合硝苯地平控释片治疗高血压比单用厄贝沙坦/氢氯噻嗪片或硝苯地平控释片更有效、安全,值得推广。

       

      Abstract: Objective: To observe the efficacy of irbesartan/hydrochlorothiazide tablets(IHT) and nifedipine controlled-release tablets (NCRT) in moderate to severe essential hypertension. Methods: Patients were randomly divided into A group(IHT 150 mg,per day, n=21),B group(NCRT 30 mg per day,n=25),C group(150 mg per morning,NCRT 30 mg per night,n=32),three groups were all treated for 12 weeks. Results: Blood pressure of three groups all greatly decreased(P < 0.01),the total effective rate in IHT groups was 61.9%; the total effective rate in NCRT groups was 64.0% the total effective rate in IHT + NCRT groups was 93.8%. Conclusions: IHT plus NCRT are more efficiency than IHT or NCRT group in the treatment of moderate to severe hypertension. So it deserve to popularize fore more efficiency and more security.

       

    /

    返回文章
    返回